Sino Biopharmaceutical – World Class Benchmarking
Company: Sino Biopharmaceutical Limited
Bloomberg ticker: 1177 HK
Market cap: US$20,172m
Background: Sino Biopharmaceutical Limited is an investment holding company engaged in the pharmaceuticals business. The company conducts R&D, produces, and sells biopharmaceutical products for the treatment of ophthalmia, and modern Chinese medicine, and chemical medicine for the treatment of hepatitis.
World Class Benchmarking of Sino Biopharmaceutical
- Profitable Growth rank of 4 was up compared to the prior period’s 5th rank
- This is above average performance compared to 380 large Health Care companies worldwide
- Profitability rank of 3 was better than its Growth rank of 4
- Profitability rank of 3 was up compared to the prior period’s 5th rank
- This is above average performance compared to peers
- Growth rank of 4 was up compared to the prior period’s 7th rank
- This is above average performance compared to peers
DISCLAIMER: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may include errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.